Biotech startup Cyterix Pharmaceuticals Inc. raised $9.2 million from The Column Group and SV Life Sciences in a Series A financing.
The San Francisco company, founded by academics Steve Everett and Paul Ortiz de Montellano and the late biotech entrepreneur John Curd, is working to discover and develop drugs that target certain enzymes that are highly over-expressed in many cancers. Specifically, it targets extra-hepatic cytochrome P450 enzymes.
No comments:
Post a Comment